Newsletter Signup x
Current treatments for childhood acute lymphoblastic leukaemia (ALL) are highly toxic. In this project Professor Enver and his team hope to identify drugs that target specific vulnerabilities of leukaemia cells and combine them together to effectively eradicate the leukaemia cells without harming normal cells.
Targeting RUNX/Core Binding Factor-dependency in relapsed and poor prognosis acute lymphoblastic leukaemia
Professor Tariq Enver
UCL Cancer Institute
London, WC1E 6BT
1 July 2017
56 months
£182,907
Patient Story – Archer
Archer was diagnosed with high-risk neuroblastoma on 30 December 2021 when he was just two years old. His mum
Read moreAn international network understanding the long-term impacts for medulloblastoma survivors
We need to understand the long-term impact of treatments used for children who survive medulloblastoma. Forming a unique team
Read morePatient Story – Isabellah
Isabellah was diagnosed with embryonal rhabdomyosarcoma on 27 August 2021 when she was three years old. Her mum Amy
Read more